Tissue Characterization in ST-Segment Elevation Myocardial Infarction: A Multicenter Registry of Patients Evaluated With Cardiac Magnetic Resonance
Sponsor study identifier
observational
500
1 country
3
Study Start
January 1, 2025
Actual (reported)Primary Completion
September 30, 2025
Actual (reported)Study Completion
December 31, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This multicenter registry includes patients with a first ST-segment elevation myocardial infarction (STEMI) who underwent cardiac magnetic resonance (CMR) imaging during the acute phase and follow-up. The registry is designed to identify clinical and CMR-derived predictors of adverse ventricular remodeling and major adverse cardiac events (MACE). CMR provides accurate and reproducible assessment of infarct size, left ventricular function, microvascular obstruction, and tissue characteristics, enabling detailed prognostic modeling.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2025
Actual (reported)September 30, 2025
Actual (reported)November 25, 2025
Actual (reported)December 18, 2025
Actual (reported)December 31, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Incidence of MACE (Major Adverse Cardiac Events)
The primary endpoint is the occurrence of MACE during follow-up. MACE is defined as a composite of the following events: Cardiac death (death attributable to cardiovascular causes) Heart failure hospitalization (unplanned admission with a primary diagnosis of heart failure) Heart transplantation or durable mechanical circulatory support Appropriate ICD therapy (appropriate shock or anti-tachycardia pacing for ventricular arrhythmia in patients with implantable defibrillators). The occurrence of the first event in the composite will be used for time-to-event analyses. The first event in the composite will be used for time-to-event analyses. Event classification will be determined according to standardized definitions and based on review of available medical records.
From hospital discharge (or index CMR) to at least 6 months, with extended follow-up planned for as long as 5 years, subject to data availability.
Patients admitted with a first STEMI treated with primary PCI, evaluated by CMR in the acute phase and follow-up
The study population consists of patients admitted with a first ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) and were evaluated by cardiac magnetic resonance (CMR) both in the acute phase and during follow-up. The study is conducted in tertiary academic hospitals with well-established CMR programs, ensuring standardized imaging protocols and high-quality data acquisition. Participating centers include the Hospital Clínic de Barcelona, the Hospital Clínico Universitario de Valencia, and the Hospital Universitari Vall d'Hebron, all located in Spain.
Hospital Vall d'Hebron de Barcelona
Barcelona, 08035, Spain
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
Hospital Clínico de Valencia
Valencia, 46010, Spain
500 participants (actual enrollment reported by the registry).
First Submitted
November 25, 2025
First Posted
December 18, 2025
Study Start
January 1, 2025
Actual (reported)Functional Magnetic Resonance Imaging Study on the Role of Awareness in Visual Perception in Healthy Adult Subjects.
Contact the study team to confirm eligibility.
Primary Completion
September 30, 2025
Actual (reported)Study Completion
December 31, 2036
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
December 18, 2025
Record last verified: 2025-10
De-identified individual participant data (IPD) will not be shared because data sharing is not planned for this study.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: